Taking Quinazoline as a General Support-Nog to Design Potent and Selective Kinase Inhibitors: Application to FMS-like Tyrosine Kinase 3

机译：以喹唑啉作为一般支持物来设计有效和选择性激酶抑制剂：在类似FMS的酪氨酸激酶3中的应用

获取原文

页面导航

著录项
相似文献
相关主题

著录项

来源
《ICMSI;International conference of molecular simulations and applied informatics technologies》|2010年|p.67-70|共4页
会议地点 Wuhan(CN);Wuhan(CN)
作者
Wei-Wei Li; Luo-Ding Yu; Li-Juan Chen; Yu-Quan Wei; Sheng-Yong Yang; Jin-Juan Chen; Ren-Lin Zheng; Wen-Qin Zhang; Zhi-Xing Cao; Ling-Ling Yang; Xiao-Yu Qing; Liang-Xue Zhou; Li Yang;
展开▼
作者单位

State Key Laboratory of Biotherapy West China Hospital West China Medical School Sichuan University No.1 Keyuan Si Road High Tech Park Chengdu 610041 (China) College of Chemical Engineering Sichuan University No.24 South Section 1 Yihuan Road Chengdu 610065 (China);

State Key Laboratory of Biotherapy West China Hospital West China Medical School Sichuan University No.1 Keyuan Si Road High Tech Park Chengdu 610041 (China);

State Key Laboratory of Biotherapy;

展开▼
会议组织
原文格式 PDF
正文语种
中图分类
关键词
入库时间 2022-08-26 14:40:28

相似文献

外文文献
中文文献
专利

1. Taking Quinazoline as a General Support-Nog to Design Potent and Selective Kinase Inhibitors: Application to FMS-like Tyrosine Kinase 3 [J] . Wei-Wei Li, Jin-Juan Chen, Ren-Lin Zheng ChemMedChem . 2010,第4期

机译：以喹唑啉作为一般支持物来设计有效和选择性激酶抑制剂：在FMS样酪氨酸激酶3中的应用
2. Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3) [J] . Poulsen A., William A., Blanchard S., Journal of molecular modeling . 2013,第1期

机译：基于结构的氮连接大环激酶抑制剂的设计导致临床候选药物SB1317 / TG02，这是细胞周期蛋白依赖性激酶（CDK），Janus激酶2（JAK2）和Fms样酪氨酸激酶3（FLT3）的有效抑制剂。
3. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5, 7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer [J] . William A.D., Lee A.C.-H., Goh K.C., Journal of Medicinal Chemistry . 2012,第1期

机译：发现激酶光谱选择性大环（16E）-14-甲基-20-oxa-5，7,14,26-四氮杂四环[19.3.1.1（2,6）.1（8,12）] heptacosa-1（25），2（26），3,5,8（27），9,11,16,21,23-癸烯（SB1317 / TG02），一种有效的细胞周期蛋白依赖性激酶（CDKs）抑制剂，Janus激酶2（JAK2），和Fms样酪氨酸激酶3（FLT3）用于治疗癌症
4. Taking Quinazoline as a General Support-Nog to Design Potent and Selective Kinase Inhibitors: Application to FMS-like Tyrosine Kinase 3 [C] . Wei-Wei Li, Luo-Ding Yu, Li-Juan Chen, International conference of molecular simulations and applied informatics technologies . 2010

机译：将喹唑啉作为一般支持Nog设计有效和选择性激酶抑制剂：在FMS样酪氨酸激酶3中施用
5. Pharmacological Characterization of TAS05567, a Potent and Selective Inhibitor of Spleen Tyrosine Kinase, in Animal Models of Inflammatory Diseases and B-cell Malignancies [D] . 林宏明 2019

机译：TAS05567，脾酪氨酸激酶的强效和选择性抑制剂，在炎症性疾病和B细胞恶性动物模型中的药理特性
6. Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms [O] . Peter P. Ruvolo, Huaxian Ma, Vivian R. Ruvolo, 2017

机译：Anexelekto / MER酪氨酸激酶抑制剂ONO-7475通过多种机制阻止生长并杀死FMS样酪氨酸激酶3内部串联复制突变型急性髓细胞白血病细胞
7. Selective Cytotoxic Mechanism of GTP-14564, a Novel Tyrosine Kinase Inhibitor in Leukemia Cells Expressing a Constitutively Active Fms-like Tyrosine Kinase 3 (FLT3) [O] . Ken Murata, Hidetoshi Kumagai, Toshiyuki Kawashima, 2003

机译：GTP-14564的选择性细胞毒理机制，一种表达组成型活性FMS酪氨酸激酶3（FLT3）的白血病细胞中的新型酪氨酸激酶抑制剂

Taking Quinazoline as a General Support-Nog to Design Potent and Selective Kinase Inhibitors: Application to FMS-like Tyrosine Kinase 3

著录项

相似文献

相关主题

期刊订阅